Radiotherapy for Growing Vestibular Schwannomas: Real‑World Tumor Control and What It Means for Practice
Posted innews Oncology Otorhinolaryngology

Radiotherapy for Growing Vestibular Schwannomas: Real‑World Tumor Control and What It Means for Practice

An international multicenter cohort of 1,883 patients with radiologically growing vestibular schwannomas treated first‑line with radiotherapy showed a 10‑year tumor control rate of 76.1% (primary definition). Control estimates varied widely by growth definition, underscoring the clinical importance of outcome metrics.
Adenotonsillectomy vs Watchful Waiting in Young Children with Mild–Moderate OSA: Long-term Findings from the KATE Randomized Trial
Posted innews Otorhinolaryngology Pediatrics

Adenotonsillectomy vs Watchful Waiting in Young Children with Mild–Moderate OSA: Long-term Findings from the KATE Randomized Trial

The KATE trial (n=60) found no between-group difference in polysomnographic OAHI change after 3 years, though adenotonsillectomy improved disease-specific quality of life. Nearly 42% of watchful-waiting children later underwent surgery, suggesting watchful waiting is reasonable for selected young children with mild OSA and small tonsils but requires close follow-up.
Temporary Inpatient Hemodialysis Access for Uninsured Patients Is Associated with Shorter Hospital Stays in a County Safety-Net System
Posted inNephrology news Public Health

Temporary Inpatient Hemodialysis Access for Uninsured Patients Is Associated with Shorter Hospital Stays in a County Safety-Net System

A Los Angeles County quality-improvement study found that regulatory approval allowing an inpatient hemodialysis unit to provide transitional outpatient dialysis to uninsured patients initiating hemodialysis was associated with a substantial, sustained reduction in hospital length of stay.
Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know
Posted inCardiology news Oncology

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know

A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Trial selection and monitoring practices limit generalizability; baseline cardiac assessment and individualized surveillance remain essential.
Therapist-Guided e‑Health Cuts Fear of Cancer Recurrence in Colorectal Survivors: A Randomized Trial Shows Clinically Meaningful Benefits
Posted inAI news Oncology

Therapist-Guided e‑Health Cuts Fear of Cancer Recurrence in Colorectal Survivors: A Randomized Trial Shows Clinically Meaningful Benefits

A Danish RCT of TG‑iConquerFear, a 10‑week therapist‑guided online program for colorectal cancer survivors with clinical fear of cancer recurrence (FCR), reduced FCR scores substantially compared with augmented self‑help at 3 months; the between‑group effect was clinically meaningful (Cohen d 0.62).
Neural Networks Predict Survival for Older Adults With Head and Neck Cancer — Useful, but Not Yet Practice-Changing
Posted innews Oncology Otorhinolaryngology

Neural Networks Predict Survival for Older Adults With Head and Neck Cancer — Useful, but Not Yet Practice-Changing

An international cohort study developed and externally validated artificial neural networks that stratify older adults with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiation. Models showed moderate discrimination (OS AUC 0.68, PFS AUC 0.64) with HPV status, kidney function, ECOG, and nodal stage among top predictors.